Patents Assigned to ANTECIP BIOVENTURES II LLC
  • COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING MUSCULOSKELETAL PAIN
    Publication number: 20140249108
    Abstract: Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions.
    Type: Application
    Filed: May 15, 2014
    Publication date: September 4, 2014
    Applicant: Antecip Bioventures II LLC
    Inventor: Herriot Tabuteau
  • Compositions for oral administration of zoledronic acid or related compounds for treating disease
    Patent number: 8822436
    Abstract: Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions. The oral bioavailability of zoledronic acid can be enhanced by administering the zoledronic acid in the disodium salt form.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: September 2, 2014
    Assignee: Antecip Bioventures II LLC
    Inventor: Herriot Tabuteau
  • Compositions for oral administration of zoledronic acid or related compounds for treating disease
    Patent number: 8802658
    Abstract: Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions. The oral bioavailability of zoledronic acid can be enhanced by administering the zoledronic acid in the disodium salt form.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: August 12, 2014
    Assignee: Antecip Bioventures II LLC
    Inventor: Herriot Tabuteau
  • Compositions for Oral Administration of Zoledronic Acid or Related Compounds for Treating Disease
    Publication number: 20140107345
    Abstract: Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions.
    Type: Application
    Filed: December 13, 2013
    Publication date: April 17, 2014
    Applicant: Antecip Bioventures II LLC
    Inventor: Herriot Tabuteau
  • Compositions for Oral Administration of Zoledronic Acid or Related Compounds for Treating Disease
    Publication number: 20140051669
    Abstract: Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions.
    Type: Application
    Filed: October 25, 2013
    Publication date: February 20, 2014
    Applicant: Antecip Bioventures II LLC
    Inventor: Herriot Tabuteau
  • Compositions and Methods Comprising Celecoxib or Related Compounds and Dextromethorphan
    Publication number: 20140051718
    Abstract: Neurological disorders may be treated by administering a therapeutically effective amount of dextromethorphan and a therapeutically effective amount of a compound such as celecoxib that inhibits the metabolism of dextromethorphan, to a person in need thereof. The two compounds may be administered separately, or in a single dosage form or composition as described herein.
    Type: Application
    Filed: July 16, 2013
    Publication date: February 20, 2014
    Applicant: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Compositions and methods comprising tilidine or related compounds and dextromethorphan
    Patent number: 8569328
    Abstract: Pain and/or neurological disorders may be treated by administering a therapeutically effective amount of dextromethorphan and a therapeutically effective amount of a compound such as tilidine that inhibits the cytochrome P450 isozyme CYP2D6, to a person in need thereof. The two compounds may be administered separately, or in a single dosage form or composition as described herein.
    Type: Grant
    Filed: May 22, 2012
    Date of Patent: October 29, 2013
    Assignee: Antecip Bioventures II LLC
    Inventor: Herriot Tabuteau
  • Implantable Polymeric Device for Sustained Release of Sufentanil
    Publication number: 20120288551
    Abstract: Extended release of sufentanil is provided by implanting a device containing sufentanil into a mammal or human being. The device may include a solid biocompatible polymer matrix, and sufentanil may be encapsulated within the polymer matrix. The polymer matrix comprises a plurality of pores configured to allow contact between the sufentanil and a physiological fluid of a mammal into which the device is implanted to thereby release sufentanil in vivo from the device into the mammal. The devices may be used to treat opioid addiction or pain.
    Type: Application
    Filed: May 10, 2012
    Publication date: November 15, 2012
    Applicant: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau